Introduction
The beneficial effects of cardiac rehabilitation (CR) that have been reported for more than 40 years 1 are not universally accepted. In particular, early reported mortality effects are disputed. Recently, West et al. 2 argued that pooled data of studies published after the landmark WHO European multicentre collaborative trial (early 1970s) did not evidently show a mortality reduction by CR in myocardial infarction (MI) patients. Also, in the recent Rehabilitation After Myocardial Infarction Trial (RAMIT), conducted in Great Britain, no beneficial effects of CR on short-term and long-term mortality were seen in MI patients mainly treated with thrombolysis. 2 An additional concern for the need of CR in modern era acute coronary syndrome (ACS) patients may be the excellent overall prognosis of treated patients with an ACS with clear improvements in invasive and non-invasive medical treatment. Modern era AMI patients are in particular at lower risk because treatment with primary percutaneous coronary intervention (pPCI) has substantially reduced mortality. 3, 4 On top of this, nowadays medical therapy is (close) to optimal from peri-and post-pPCI, including standard treatment with statins and dual antiplatelet therapy. 5 So, it may be expected that such patients even less benefit from CR. 6 Therefore,
Taylor et al. 6 suggested to focus on seeking for the evidence of reduction in hospital readmission and health-related quality of life, rather than on a reduction of mortality. But, surprisingly, de Vries et al. 7 recently reported in a retrospective analysis, beneficial effects of CR on mortality in a subset of patients with an ACS, included from 2007 to 2010. It might be that because of the early discharge of this relatively low-risk modern-time ACS patients, CR can be valuable to guide patients towards a personal health plan, for which there is little time during the short hospitalization. 8 Also, a major flaw in many CR trials that may explain contradictory findings is that it is not clear what part of the CR program was actually followed by the patient because the definition of participation was lacking 2 or attendance of at least only one session was already defined participation. Because of the concerns and contradictory findings of the beneficial effects of CR on mortality in the modern era ACS patient, we conducted a large study to assess the effects of CR in patients after ACS treated with pPCI on long-term mortality, in particular in patients who completed the CR program, compared with those patients who did not complete the CR program.
Methods Patients
The 
Cardiac rehabilitation
The program focuses on improving physical condition, self-confidence, and social integration. The multidisciplinary CR program is led by a physician, specialized physiotherapists, nurses, and social workers. The core of the program consists of 1.5 h group exercise sessions 2 times a week during a maximum of 12 weeks at local sport's accommodations. Besides the exercise program, both verbal and written instructions are given on how to deal with exercise, diet, smoking cessation, and stress management. The aim is to improve adherence to lifestyle modification and to help patients to adopt a positive role in the care of their own health. If necessary, individual consultations with psychiatrist, psychologist, social workers, and dieticians are provided. The exact length of a CR program is determined by a multidisciplinary team together with the patient but with a minimum of 6 weeks. Upon completion of the CR program, a maximum (symptom-limited) bicycle stress test is performed. Patients who had completed CR program had attended at least 75% of the physical program: this was our definition of 'completed CR'. 10 
Statistical analysis
Continuous variables are presented as mean ± standard deviation, whereas categorical variables are expressed as percentages. Comparisons among groups were performed by the independent t-test for continuous variables and Pearson's v 2 test for categorical variables. All statistical tests were two-tailed and a P-value of <0.05 was considered statistically significant. The incidence of events over time was studied with the use of the Kaplan-Meier method, whilst log-rank tests were applied to evaluate differences between the treatment groups. Patients lost to follow-up were considered at risk until the date of last contact, at which point they were censored. Cox regression analysis was performed to adjust CR effect for the following potential confounders: to generate a propensity score for CR participation using the following characteristics ( 
Primary endpoint
For information about mortality municipality live registries were studied. Nine patients were lost to follow-up (0.9%).
Results
Cardiac rehabilitation participants vs. non-cardiac rehabilitation participants 
Cardiac rehabilitation participants: complete vs. non-complete Cardiac rehabilitation
Nine-hundred and fifteen (78.9%) patients completed CR. Clinical characteristics between complete CR and non-complete CR patients are displayed in Table 2 . Patients who did not complete CR had more often diabetes (12.3% vs. 18 .4%). Cumulative mortality rates at 5 and 10 years were 5.5% and 13.6% in the complete CR and 8.6% and 18.9% in the non-complete CR patients group (Figure 2) . Complete CR patients had a 48% lower 10-year mortality than non-complete CR patients (HR 0.521, 95% CI 0.405-0.672). After adjustment complete CR patients had a 46% lower 10-year mortality (HR 0.54, 95% CI 0.42-0.70; P < 0.001) than non-complete CR patients.
Discussion
The main findings of this study in ACS patients treated with pPCI are (i) patients who attended a CR program had significantly lower 10-year mortality than their no-CR counterparts and (ii) patients who completed CR had a lower 10-year mortality when compared with patients who started but did not complete CR. This confirms that despite major changes in ACS treatment, CR programs may still be beneficial in terms of 10-year survival in the pPCI era.
To the best of our knowledge our propensity matched study is the first which studied the relationship between long-term effects of CR on mortality in ACS patients treated with pPCI which is the currently recommend treatment for not only STEMI patients but also in most patients with non-STEMI. 13, 14 Despite these major changes in treatment in the acute phase of ACS beneficial effects of CR seem still prominent, evidenced by a 39% reduction in mortality. One of the reasons for failure to demonstrate positive effects on mortality by others in different populations may be the existing different definitions and lengths of CR programs attendance. 7 Sometimes, attendance of only one session was already defined as participation. Therefore, we also assessed the outcome of patients who did and did not complete CR. Patients who completed CR had a 10-year mortality of 13.6% against 18.9% in patients who did not complete CR. Thus, there seems to be a 'dose response curve' with greater reduction in mortality with full completion of CR. This was already mentioned by Beauchamp et al. 10 who studied patients undergoing bypass surgery. Patients who attended less than 25% of the CR program had a mortality risk over twice that of patients who attended more than 75% of the program. In our experience, patient motivation is the most important reason in completing CR, although we cannot substantiate this with scientific evidence. When compared with the recent study by de Vries et al., 15, 16 we did have information on cardiovascular risk factors whereas they did not: but this was not a major confounder in our study. Logistic reasons such as transportation facilities and the distance to the nearest CR centre have shown to be crucial in CR participation. Finally, the expected effects of CR by the patient may play an important role.
One of the main challenges in post-ACS management is to increase patient participation in CR programs. As we recently demonstrated, in the Rotterdam-Rijnmond region, only 39% of eligible patients participated in CR, which is exemplary for a broad range of clinical practices. 15, 17 Target populations including women, elderly and patients with low socioeconomic status have poorer than average participation rates and need specific attention. 18 Therefore, before patients can get the benefits of CR and even better completion of CR, they first have to be referred by their cardiologists. This is still a challenge worldwide.
Since there seems to be a 'dose response curve' with greater reduction in mortality with full completion of CR, we strongly advocate a strict definition of CR. Rauch et al. 19 in their systematic review and meta-analysis ('Cardiac Rehabilitation Outcome Study-analysis') already emphasize the need for defining internationally accepted CR standards, since they found a wide heterogeneity of CR programmes. Given the results of our current study, we plea that CR be defined 'complete' if a patient participated in at least 75% of the full multidisciplinary CR program. Our work can be considered a valuable contribution to review by Rauch et al., 19 as our follow-up period was much longer and even then survival benefit was sustained. Furthermore, our patients constituted a more homogeneous population. In particular, all patients had ACS that was treated with pPCI, and there were no differences in the use of guideline-recommended 'optimal' medical therapy between the patients with complete and incomplete CR. Even in such a homogeneous group, CR in the new millennium showed to be beneficial for long-term survival.
Limitations
Our study had an observational retrospective design. Although we performed propensity matching and multivariate Cox regression, we could not control for all confounders.
Conclusion
Acute coronary syndrome patients treated with pPCI who attended a CR program had significantly lower 10-year mortality than their no-CR counterparts. Also, patients who completed CR had a better prognosis when compared with patients who started but did not complete CR. This suggests that despite changes in treatment of
